Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Using a new method of indocyanine green for liver surgery imaging

Official title: Application of Indocyanine Green(ICG)@Human Serum Albumin(HSA) Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection: A Prospective, Double-Blinded, Randomized Controlled Trial

Run by West China Hospital · NCT06219096 · Data updated 2026-11-12

This study is testing a new way of using a special dye during liver surgery to see if it helps doctors find tumors better compared to the usual method, and it's for patients with liver cancer.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment100 (estimated)
SponsorWest China Hospital
Academic / other
Locations1 site (Chengdu, Sichuan)
StatusRecruiting
StartedDecember 10, 2023
Main results expectedDecember 31, 2026
Study endsDecember 31, 2028
Registry record updatedJanuary 23, 2024
Trial IDNCT06219096 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 18-75 with primary liver malignancies who are scheduled for laparoscopic anatomical liver resection and have a Child-Pugh grade A or B liver function.

Probably not a fit

Patients with severe liver dysfunction, coagulation disorders, or those who are pregnant or lactating may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a single-center, prospective, randomized controlled trial comparing a novel indocyanine green (ICG) administration protocol with the standard protocol for fluorescence imaging during laparoscopic anatomical liver resection. The study will enroll 100 patients aged 18-75 with primary liver malignancies, randomly assigning them to either the experimental group using the new ICG-albumin protocol or the control group using the standard ICG protocol. The primary outcome will assess the efficacy of fluorescence imaging through a scoring system evaluated by independent experts. The goal is to enhance visualization of liver segments and tumor margins during surgery.

Why it matters

Potential benefit: If successful, this study could improve surgical outcomes by providing better visualization of liver tumors, potentially leading to more effective resections.

How similar studies have gone: Other studies have shown promising results with similar fluorescence imaging techniques, but this specific approach using ICG-albumin is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age: 18-75 years old, patients with hepatic malignancies who are undergoing laparoscopic anatomical liver resection;
2. Preoperative liver function Child-Pugh grade A or B;
3. No contraindications for laparoscopic liver resection;
4. Expected survival ≥3 months;
5. ECOG PS score 0-1;
6. Normal major organ functions, and meet the following laboratory test results within 7 days prior to enrollment: white blood cell (WBC) ≥2.5×10\^9/L, absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelet (PLT) ≥75×10\^9/L, hemoglobin (HGB) ≥90g/L; NR ≤1.5xULN; serum creatinine (CT) ≤1.5xULN; total bilirubin (TBI) ≤1.5×upper limit of normal (ULN);
7. Patients voluntarily participate and sign informed consent.

Exclusion Criteria:

1. No obvious ischemic demarcation line after intraoperative occlusion or disconnection of target hepatic pedicle, or the liver fluorescence reaches an intensity that interferes with surgery before intraoperative ICG injection.
2. Poor hepatic reserve function (ICG R15 ≥ 20%);
3. Severe cardiopulmonary diseases, intolerant to general anesthesia and surgery;
4. Moderate or large amount of symptomatic ascites or pleural effusion;
5. Active bleeding or coagulation abnormalities;
6. Hepatic encephalopathy;
7. Allergy to ICG;
8. History of gastrointestinal bleeding within the past 6 months or definite tendency for gastrointestinal bleeding;
9. Severe esophageal gastric varices requiring interventional treatment;
10. Objective evidence showing severe impaired pulmonary function such as pulmonary fibrosis;
11. Any significant clinical and laboratory abnormalities that the investigator considers affecting safety assessment.

Where it's running

  • West China Hospital
    Chengdu, Sichuan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.